United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Glenmark Pharmaceuticals balances modest Q1 FY26 growth with innovation drive, global partnerships and robust pipeline ambitions Glenmark’s Q1 FY26 results reveal modest growth but highlight strong specialty launches, AbbVie licensing deal, and a robust innovation pipeline. byPallavi MadhirajuAugust 18, 2025